Skip to main content
      RT @RichardPAConway: @rheum_cat presenting a really well designed study looking at association between TNFi use and inci

      Richard Conway RichardPAConway

      4 years ago
      @rheum_cat presenting a really well designed study looking at association between TNFi use and incident hypertension in axSpA. No association found. Abstr#0910 #ACR21 @RheumNow https://t.co/w7o1oDreVL
      RT @DrPetryna: Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) b

      Olga Petryna DrPetryna

      4 years ago
      Abst0569 #acr21 @RheumNow mortality in SpA:⬆️ overall mortality in AS (RR 1.64, 95% CI: 1.49-1.80,) but not PsA (RR: 1.12, 95% CI: 0.96-1.30). CV, resp & infection specific mortality significantly higher for PsA Cancer related mortality in PsA not higher than the gen pop
      RT @ericdeinmd: #ACR21 Abs#0825
      Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ)
      ⭐️Superiority f

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#0825 Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ) ⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX ⭐️ Radiographic progression low in all ▶️ Short study w very aggressive 1st line combo Rx https://t.co/TJPZkqmN8z @Rheumnow
      RT @Yuz6Yusof: #ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm
      RT @AkhilSoodMD: Abst 0562
      Ungprasert & colleagues examine hospitalization and resource utilization among patients

      Akhil Sood MD AkhilSoodMD

      4 years ago
      Abst 0562 Ungprasert & colleagues examine hospitalization and resource utilization among patients with #AnkylosingSpondylitis - Prevalence is high - Infection was among the most common reasons for hospitalization (sepsis, pneumonia, UTI) #ACR21 @RheumNow https://t.co/UftoFllE1v
      RT @ericdeinmd: #ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs
      ⭐️More pts stay on UPA vs ADA (47 vs 36%)

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs ⭐️More pts stay on UPA vs ADA (47 vs 36%) ⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq
      RT @AurelieRheumo: 🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patien

      Aurelie Najm AurelieRheumo

      4 years ago
      🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patients. Low hb at headline associated w/ MTX TNFi and ⬆️ increase in TSS. Not that surprising provided low Hb is a marker of systemic inflammation. #Abtr0786 #ACR21 @Rheumnow https://t.co/eQLGxsANkk
      RT @DrPetryna: Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progres

      Olga Petryna DrPetryna

      4 years ago
      Abst0907 #ACR21 @RheumNow observation of GLAS cohort of nrAxSpA pts over 6 yrs showed ~10% of pts progress to AS every 2 years. Specifically after two, four and six years, 8/79 (10.1%), 4/48 (8.3%) and 3/24 (12.5%) nr-axSpA patients progressed to AS. https://t.co/hVpNz1kEgE
      RT @KDAO2011: Can RA be cured?
      Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy

      TheDaoIndex KDAO2011

      4 years ago
      Can RA be cured? Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy given by SQ injx; it's presented by LN-DCs causing: CTL exhaustion while controlling autoreactive CD4+ T cells #ACRbest @rheumnow #ACR21 Abst#0967should have been a plenary! https://t.co/6ZzDgavafS
      RT @DrMiniDey: Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression?

      Mrinalini Dey DrMiniDey

      4 years ago
      Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression? #ACR21 Abs#0787 👉🏼Sustained improvements in Hb when treated with bio/non-bio DMARDs 👉🏼Low Hb assoc with incr radiographic progression @RheumNow https://t.co/DWgoiqYfAt https://t.co/aSRCT2vGjW
      RT @swethaann23: Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study e

      swethaann23 swethaann23

      4 years ago
      Prospective multicenter Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study evaluated 240 patients with axSpA ⭐️Imaging of the SIJ and spine DOES NOT differ in Ps axSpA or axSpA associated with iritis or colitis Abst# 0902 #ACR21 #ACRBest @RheumNow https://t.co/Y2bRlysXI5
      RT @RichardPAConway: Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, whi

      Richard Conway RichardPAConway

      4 years ago
      Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd
      RT @RichardPAConway: @KronzerMD @jeffsparks on association of respiratory diseases with incident RA. Upper airway diseas

      Richard Conway RichardPAConway

      4 years ago
      @KronzerMD @jeffsparks on association of respiratory diseases with incident RA. Upper airway diseases (sinusitis, pharyngitis) seem to associate even more strongly than asthma/COPD. Abstr#564 #ACR21 @RheumNow https://t.co/HvoBOs3OOF
      RT @synovialjoints: The rate of progression of nr-axSpA to AS is ~10% every 2 years. Study of 79 patients over 6 years,

      Dr. Antoni Chan synovialjoints

      4 years ago
      The rate of progression of nr-axSpA to AS is ~10% every 2 years. Study of 79 patients over 6 years, radiographic progression was 10.1% after 2 years (8/79), 8.3% between 2-4 years (4/48), and 12.5% between 4-6 years (3/24) @RheumNow #ACR21 Abst#0907 https://t.co/hOhpngANIl https://t.co/PiKDgiTES2
      ×